A share price of Alkermes plc [ALKS] is currently trading at $30.17, down -1.73%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ALKS shares have gain 1.51% over the last week, with a monthly amount drifted -2.87%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Alkermes plc [NASDAQ: ALKS] stock has seen the most recent analyst activity on September 26, 2025, when RBC Capital Mkts upgraded its rating to a Outperform but kept the price target unchanged to $44 for it. Previously, Wells Fargo started tracking the stock with Overweight rating on September 03, 2025, and set its price target to $44. On July 15, 2025, Goldman initiated with a Buy rating and assigned a price target of $43 on the stock. UBS upgraded its rating to a Buy but stick to its price target of $42 on June 17, 2025. Needham initiated its recommendation with a Buy and recommended $45 as its price target on May 28, 2025. RBC Capital Mkts started tracking with a Sector Perform rating for this stock on March 13, 2025, and assigned it a price target of $40. In a note dated March 04, 2025, UBS upgraded a Neutral rating on this stock and boosted its target price from $21 to $38.
Alkermes plc experienced fluctuations in its stock price throughout the past year between $25.17 and $36.45. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Alkermes plc [NASDAQ: ALKS] shares were valued at $30.17 at the most recent close of the market. An investor can expect a potential return of 52.47% based on the average ALKS price forecast.
Analyzing the ALKS fundamentals
Trailing Twelve Months sales for Alkermes plc [NASDAQ:ALKS] were 1.52B which represents 4.24% growth. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.21 and Total Capital is 0.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.68 points at the first support level, and at 29.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.68, and for the 2nd resistance point, it is at 31.18.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Alkermes plc [NASDAQ:ALKS] is 3.67. Further, the Quick Ratio stands at 3.27, while the Cash Ratio is 1.3. Considering the valuation of this stock, the price to sales ratio is 3.27, the price to book ratio is 2.87 and price to earnings (TTM) ratio is 14.93.
Transactions by insiders
Recent insider trading involved Hopkinson Craig C., EVP R&D, Chief Medical Officer, that happened on Nov 03 ’25 when 9000.0 shares were sold. Officer, Hopkinson Craig C. completed a deal on Nov 03 ’25 to buy 9000.0 shares. Meanwhile, EVP R&D, Chief Medical Officer Hopkinson Craig C. sold 9000.0 shares on Oct 15 ’25.
